TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05862857

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV-focused mobilization
Description: Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free HIV testing at the local clinic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-disease-focused mobilization
Description: Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free health screenings that may include hypertension, diabetes, HIV, malaria (if febrile), and TB (if symptomatic), and pregnancy at the local clinic
Study: NCT05563792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Options for Pain Management using Non-medication Strategies
Description: The purpose of this study is to help Veterans learn about different ways they can manage chronic pain that do not involve medications. Veterans will work with a coach to explore their values and goals and how different non-medication approaches may fit into these values and goals.
Study: NCT05793541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone call
Description: A phone call from a trained study clinician that uses a standardized phone script to (a) conduct a risk assessment and (b) recommend that the participant use their safety plan (any and all included components), which will be reviewed and revised as-needed during the call. This intervention occurs at High Risk only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: A text message conversation initiated by a trained study clinician that uses a standardized text messaging script to (a) conduct a risk assessment and (b) recommend that the participant use their safety plan (any and all included components), which will be reviewed and revised as-needed during the text messaging interaction. This intervention occurs at High Risk only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated interactive smartphone-based tool
Description: An automated interactive, smartphone-based tool that will (a) (at High Risk only) guide the participant through a risk assessment and (b) (at High and Medium/Low Risk) present recommendation to use and a review of the safety plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-interactive pop-up messages
Description: Automated non-interactive, static pop-up messages that recommend use of the safety plan or its components (Medium/Low Risk only).
Study: NCT05885282

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paraspinal vibration
Description: In addition to lumbar spinal stabilization exercises, LV will be applied to the cervical and lumbar paraspinal muscles. Spinal stabilization exercises will be as in the control group. The duration of a session will be 50 minutes, with spinal stabilization exercises 40 minutes and LV 10 minutes.LV will be applied before the exercises. LV will be applied to the cervical paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are in a sitting position. LV will be applied to the lumbar paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gastrosoleus muscle complex vibration
Description: In addition to lumbar spinal stabilization exercises, LV will be applied to the gastrosoleus muscle complex. LV application will be applied sequentially, bilaterally, to the gastrosoleus complex. LV will be applied before the exercises. LV will be applied for a total of 10 minutes (5 minutes each on the right and left) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Exercise
Description: Lumbar spinal stabilization exerciseswill be given. Lumbar spinal stabilization exercises; Diaphragmatic breathing, and contraction of the transversus abdominis and multifidus muscles will be taught in the supine position. Activation of these muscles will be studied in different positions (prone, crawling, sitting, and sitting on different surfaces). The focus will be on increasing kinesthetic awareness. It will be desirable to ensure and maintain the activation of these muscles during subsequent exercises. Exercises will be continued according to the patient's functional status and individual needs. Advancement of exercises; extremity movements on dynamic surfaces, narrowing of support surfaces, reciprocal movements, increasing the number of resistance and repetitions. The duration of a session will be 40 minutes.
Study: NCT05477277

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MAsS
Description: Add MAsS to standard of care MRI scan
Study: NCT06667661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shining Star mHealth App
Description: The Shining Star mHealth App Intervention is a 12-week mobile health program designed to improve adherence to the 24-Hour Movement Guidelines (physical activity, screen time, and sleep) among preschool-aged children (3-4 years old). The intervention delivers weekly behavior-related goals and educational lessons to parents through a mobile app, including concise messages (\&lt;500 characters) and links to additional resources. The app also includes gamification features, behavior trackers, and a \&#34;Kids Corner\&#34; for child-friendly content. Parents receive reminders and can engage with other participants through an optional chat forum.
Study: NCT06667479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) - Cold Tub Immersion (CI)
Description: Once thermoneutral procedures are complete, participants in the CI group will be seated in the cold tub and submerged into the water (10º C). The sternal notch of each participant will be used as the anatomical marker to mark submersion point. Participants will sit with both arms outstretched underwater with their backs not touching the sides of the tub. Participants with a shorter stature will be provided an underwater cushion to meet the submersion requirements. The 4-minute timer will begin once confirmation of the participants submersion level and posture is determined. Once completed, the participant will be instructed to slowly exit the tub and allowed to dry and change as necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) - Cold Shower (CS)
Description: Once thermoneutral procedures are complete, participants in the CS group will be instructed to enter the research shower area. Within the shower area, the walls of the shower will be numbered from 1 to 4, with 1 defined as facing the faucet, 2 defined as 90° to the right of side 1, 3 defined as 180° from the faucet, and 4 defined as 270° to the right or 90° C to the left from side 1. Participants will be instructed to turn 90° to the right cycling through sides 1 to 4 and then back to 1 every 15 seconds prompted by the researcher. This will allow the participant to complete four full rotations in the shower during the 4-minute intervention time. The shower faucet is modified and oriented in a way where it only produces cold water (10º C) when turned on. Once completed, the participant will be instructed to slowly exit the shower and is allowed to dry and change as necessary
Study: NCT05845775

Intervention type: PROCEDURE
Intervention: Percutaneous dilatational tracheostomy
Description: The percutaneous dilatational tracheostomy procedure will be performed via fiberoptic bronchoscopy

Intervention type: DEVICE
Intervention: Bronchoscopy
Description: Fiberoptic bronchoscopy

Intervention type: DEVICE
Intervention: ultrasonography
Description: ultrasonography

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy application
Description: Fiberoptic bronchoscopy application

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound examination
Description: Ultrasound examination
Study: NCT06287996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: footbath and actigraphy
Description: Receive warm water foot bath for 4 weeks, 1 hour before going to bed every night (7-9PM), temperature 42℃ for 20 minutes, water depth 10cm above the ankle joint and wearing an actigraphy for 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: actigraphy
Description: Wearing an actigraphy for 4 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: actigraphy
Description: Wearing an actigraphy for 4 weeks
Study: NCT04903223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg
Description: Rosuvastatin will be administered to all participants on Study Day #2
Study: NCT04886427

Intervention type: OTHER
Intervention: No intervention
Description: Measure the experiences of the current care

Intervention type: OTHER
Intervention: No intervention
Description: Measure the experiences of the current care
Study: NCT05368181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone starts with the dose of 2 mg/kg for 5 days. If no signs of aGvHD, the dose of methylprednisolone is gradually taper with the following 16 days.
Study: NCT05635292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-CBT
Description: 8 weekly 1-hr telemedicine visits with a licensed Ph.D. psychologist from the University of Pennsylvania (permissible to practice across state lines under PSYPACT), plus usual care and referral to an IBD Help Center (email, phone, online chat with IBD information specialist)
Study: NCT04504643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology-assisted circuit training
Description: Circuit training assisted by Fitlight™ 3 times a week for one hour during 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional circuit training
Description: Conventional circuit training including single and dual task 3 times a week for one hour during 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic walking
Description: Classic nordic walking 3 times a week for one hour during 8 weeks
Study: NCT06540001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated visual acuity
Description: The automated visual acuity device is developed in collaboration with Tan Tock Seng Hospital, Singapore Institute of Technology and Nanyang Technological University. It uses artificial intelligence for pose estimation and speech recognition to infer if the participant is reading the correct letters displayed on the screen.
Study: NCT05043402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: navicixizumab
Description: navicixizumab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: navicixizumab
Description: navicixizumab IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xerna™ TME Panel
Description: RNA-seq-based biomarker platform that classifies any given patient tumor sample into phenotypes based on the dominant biology of the tumor microenvironment (TME).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xerna™ TME Panel
Description: RNA-seq-based biomarker platform that classifies any given patient tumor sample into phenotypes based on the dominant biology of the tumor microenvironment (TME).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xerna™ TME Panel
Description: RNA-seq-based biomarker platform that classifies any given patient tumor sample into phenotypes based on the dominant biology of the tumor microenvironment (TME).
Study: NCT06516627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Labels
Description: Products that meet Guiding Stars' criteria for earning 1 or more Guiding Star will display labels indicating their healthfulness using star ratings: 1 star (Good), 2 stars (Better), or 3 stars (Best).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Labels
Description: Products that meet Guiding Stars' criteria for earning 1 or more Guiding Star will display labels indicating their healthfulness using star ratings: 1 star (Good), 2 stars (Better), or 3 stars (Best).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Labels
Description: Products that meet Guiding Stars' criteria for earning 1 or more Guiding Star will display labels indicating their healthfulness using star ratings: 1 star (Good), 2 stars (Better), or 3 stars (Best).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spectrum Labels
Description: All products will display an expanded Guiding Stars label that show an overall rating indicating their healthfulness using star ratings: 1 star (Poor), 2 stars (Fair), 3 stars (Good), 4 stars (Better), or 5 stars (Best).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FDA High In Labels
Description: Products that contain high levels (i.e., ≥20% DV per serving) of saturated fat, sodium, or added sugars will display a label indicating which of these nutrients the product is high in.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FDA High In Labels
Description: Products that contain high levels (i.e., ≥20% DV per serving) of saturated fat, sodium, or added sugars will display a label indicating which of these nutrients the product is high in.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FDA Traffic Light Labels
Description: All products will display a Nutrition Info label showing whether the amount of saturated fat, sodium, and added sugars in 1 serving of the product is low (\<5% DV), medium (≥5 to \<20% DV), or high (≥20% DV). Low will be shown in green, Medium in yellow, and High in red.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FDA Traffic Light Labels
Description: All products will display a Nutrition Info label showing whether the amount of saturated fat, sodium, and added sugars in 1 serving of the product is low (\<5% DV), medium (≥5 to \<20% DV), or high (≥20% DV). Low will be shown in green, Medium in yellow, and High in red.
Study: NCT06667479

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group (CO)
Description: Participants will be encouraged to maintain their current diet and exercise across the duration of the 4 week intervention. Participants will still be subjected to the pre- and post-intervention data collection session.
Study: NCT06666933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: TRE (eating is allowed from 8am to 4pm without limitation in calories) with metformin 1g bid po for 6 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Taking metformin 1g bid po only for 6 weeks as control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Taking metformin 1g bid po only for 6 weeks as control
Study: NCT06667973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Gilteritinib fumarate is an oral, selective FLT3 and AXL inhibitor. It is a type 1 inhibitor, active against both the FLT3-ITD and FLT3-TKD mutations. Gilteritinib inhibits FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and it induces apoptosis in leukemic cells expressing FLT3-ITD.~Gilteritinib is approved for the treatment of relpased/refractory FLT3-mutated AML after the successfull ADMIRAL trial. In the present study Gilteritinib (120 mg/die) in combination with FLAI will be tested as induction therapy in newly-diagnosed patients.
Study: NCT06667947

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: For the caudal block, a caudal needle was used by the same anesthesiologist after the patients were placed in the left lateral decubitus position.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: For the caudal block, a caudal needle was used by the same anesthesiologist after the patients were placed in the left lateral decubitus position.
Study: NCT06667726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorodopa F 18
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT06666868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustained CARD
Description: This group is using CARD for the 2nd year in a row in participating pharmacies as the vaccination delivery framework (It was used in the 2023-2024 fall/winter vaccination season and is now being sustained in the 2024-2025 fall/winter vaccination season).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: First-time CARD
Description: CARD is being used for the 1st time in participating pharmacies as the vaccination delivery framework (2024-2025 fall/winter vaccination season).
Study: NCT06674655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery Plus Therapeutic Exercise
Description: This group will perform three days of lumbo-pelvic motor control exercise intervention along with a motor imagery intervention program during active breaks between exercises.
Study: NCT04395183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Hydroxytryptophan 100 MG
Description: 5-HTP 100mg PO BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Hydroxytryptophan 100 MG
Description: 5-HTP 100mg PO BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate
Description: Creatine monohydrate 5g PO qday

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate
Description: Creatine monohydrate 5g PO qday

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo matched to 5-HTP
Description: placebo matched to 5-HTP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo matched to 5-HTP
Description: placebo matched to 5-HTP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose either as loose powder (matched to creatine) or encapsulated (matched to 5-HTP)
Study: NCT06050902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subclavian venipuncture for catheter placement using the needle-steering device
Description: 1. Navigation software is implemented in an ultrasound machine.~2. A linear ultrasound probe (similar in appearance to a standard ultrasound probe) is used~3. Magnetization of the puncture needle after short introduction of the needle in a dedicated device.~4. Real time needle guidance on the ultrasound screen during the puncture.
Study: NCT06218251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injections
Study: NCT05841238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study: NCT05356390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercises
Description: Stabilization training is an active form of physical therapy designed to strengthen muscles to support the spine and help prevent lower back pain.~Group A performed stabilization exercises for 4 weeks. In stabilization exercises, floor bridging, heel prop and alternate arm and leg exercises were administered in iliopsoas, gluteal and hamstring groups.~On eligible participants baseline assessment was done,3 sessions were given 3days per week, post intervention assessment was taken at 4th week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle energy techniques
Description: Muscle Energy Technique (MET) is a is a form of manual therapy, widely used in Osteopathy, that uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle.~Muscle energy techniques were given to group B. These techniques are active form of manual therapy in which patient uses its own energy on request to aid in treatment.~On eligible participants baseline assessment was done,3 sessions were given 3days per week, post intervention assessment was taken at 4th week.
Study: NCT06214858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHEN211 tablets
Description: SHEN211 tablets, tablets, specification: 0.11g, 10 tablets/box, storage: sealed, not more than 25℃ storage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHEN211 tablets
Description: SHEN211 tablets, tablets, specification: 0.11g, 10 tablets/box, storage: sealed, not more than 25℃ storage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHEN211 placebo tablets
Description: placebo tablets, tablets, specification: 0g, 10 tablets/box, storage: sealed, not more than 25℃ storage.
Study: NCT05007561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Hydrochloride
Description: oral naltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral sugar pill
Study: NCT04963894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home functional balance physiotherapy
Description: Experimental physiotherapy program is carried out at home to improve the balance of people with Parkinson's disease through exercises that simulate everyday functional contexts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Conventional control physiotherapy program is carried out face-to-face in a rehabilitation gym and in groups of 6 people. The conventional program of physiotherapy includes conventional therapeutic goals of rehabilitation in people with Parkinson's disease.
Study: NCT06139068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrative Group Counseling
Description: Two of the principles that explain how narrative therapy works are: to always maintain a stance of curiosity on the part of the practitioner and to ask questions to which the practitioner does not actually know the answers and to which the answer is known to the participants. To guide therapeutic conversations that include these questions, Michael White and David Epston have designed a series of conversation maps in the application of narrative therapy. Taking these maps into consideration, the sessions were planned with the guidance of relevant literature and structured with expert opinions. Group counseling was applied to the intervention group once a week in 8 sessions. The intervention was completed face to face, in a calm, quiet and bright environment, with a round seating plan. One session lasted 90 minutes. Each session was completed in two parts with a 10-minute break.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stress coping interviews
Description: In addition to the students' routine practices, four sessions of stress coping interviews will be held for the control group, with an interval of two weeks, after the information meeting.
Study: NCT06480760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carnosine
Description: Food ingredient (supplement)